GW Pharmaceuticals (NASDAQ:GWPH) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, March 15th.
Other research analysts have also issued reports about the company. Leerink Swann raised their price objective on GW Pharmaceuticals from $153.00 to $157.00 and gave the company an “outperform” rating in a research report on Tuesday, February 6th. Zacks Investment Research lowered GW Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Bank of America decreased their price target on GW Pharmaceuticals from $154.00 to $149.00 and set a “buy” rating for the company in a research note on Tuesday, February 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $192.00 price target (down from $208.00) on shares of GW Pharmaceuticals in a research note on Monday, February 5th. Finally, Goldman Sachs upgraded GW Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $174.00 price target for the company in a research note on Thursday, December 14th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $146.38.
Shares of GWPH stock traded down $3.47 during mid-day trading on Thursday, hitting $110.82. 185,349 shares of the company’s stock were exchanged, compared to its average volume of 254,312. The company has a quick ratio of 11.34, a current ratio of 11.44 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $3,077.47, a price-to-earnings ratio of -15.95 and a beta of 2.62. GW Pharmaceuticals has a fifty-two week low of $92.65 and a fifty-two week high of $143.37.
GW Pharmaceuticals (NASDAQ:GWPH) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.03) by ($0.40). The firm had revenue of $7.73 million during the quarter, compared to analysts’ expectations of $2.18 million. GW Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. analysts anticipate that GW Pharmaceuticals will post -9.66 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Millennium Management LLC raised its holdings in GW Pharmaceuticals by 618.1% during the fourth quarter. Millennium Management LLC now owns 198,425 shares of the biopharmaceutical company’s stock worth $26,194,000 after purchasing an additional 170,792 shares in the last quarter. Raymond James & Associates increased its holdings in shares of GW Pharmaceuticals by 9.3% in the fourth quarter. Raymond James & Associates now owns 8,464 shares of the biopharmaceutical company’s stock valued at $1,117,000 after buying an additional 718 shares in the last quarter. Ardsley Advisory Partners bought a new position in shares of GW Pharmaceuticals in the fourth quarter valued at $1,056,000. Ellington Management Group LLC bought a new position in shares of GW Pharmaceuticals in the fourth quarter valued at $1,373,000. Finally, Deutsche Bank AG increased its holdings in shares of GW Pharmaceuticals by 233.5% in the fourth quarter. Deutsche Bank AG now owns 228,206 shares of the biopharmaceutical company’s stock valued at $30,124,000 after buying an additional 159,783 shares in the last quarter. 82.51% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/gw-pharmaceuticals-plc-gwph-stock-rating-upgraded-by-bidaskclub.html.
GW Pharmaceuticals Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.